As we age, the immune system becomes constantly activated, resulting in chronic inflammation. Mitochondrial dysfunction, senescent cells, visceral fat tissue, and protein aggregates all contribute to this issue. This chronic inflammation accelerates age-related conditions, making it a major problem. Efforts to suppress excessive inflammation without affecting necessary immune function have not been successful thus far. However, there is hope that targeting inflammasomes, which play a major role in triggering the immune response, could lead to more discriminatory anti-inflammatory therapies. Research is focusing on understanding the mechanisms that regulate inflammasome assembly and activation, as well as the potential of targeting inflammasomes to treat diseases. Clinical trials are underway to evaluate the potential of inflammasome-targeting therapies, and this approach could lead to the development of novel therapeutic strategies. Therefore, understanding how inflammasomes contribute to disease pathology may have significant implications for developing new disease-modifying therapies that could be effective in several conditions.
